We chose to introduce the modification at position 353 because this site was found polyubiquitinated in PHF-tau [26,28], it is part of the fibril core found in different tauopathies [26], and mono-ubiquitination at this position had an observable influence on the aggregation kinetics without hindering the formation of short fibrils [30]. This evidence concerns the gene MAPT and tauopathy.